Literature DB >> 16879445

Atherosclerosis as a risk factor for benign prostatic hyperplasia.

Andreas P Berger1, Georg Bartsch, Martina Deibl, Hannes Alber, Otmar Pachinger, Gernot Fritsche, Barbara Rantner, Gustav Fraedrich, Leo Pallwein, Fritz Aigner, Wolfgang Horninger, Ferdinand Frauscher.   

Abstract

OBJECTIVES: To evaluate the relationship between clinical benign prostatic hyperplasia (BPH) and atherosclerosis, using colour Doppler ultrasonography (CDUS) and symptom scores. PATIENTS, SUBJECTS AND METHODS: CDUS was used to evaluate prostatic vascularity in four groups of men, comprising young healthy subjects, patients presenting with coronary artery disease (CAD), diabetes mellitus, or peripheral arterial occlusive disease (PAOD). Resistive index (RI) measurements and computer-assisted quantification of colour pixel density (CPD) were used to objectively evaluate perfusion. The International Prostate Symptom Score (IPSS) and the International Index of Erectile Function were used to quantify symptoms.
RESULTS: In diabetic patients and men with PAOD, perfusion of the transition zone (TZ) of the prostate was significantly lower (P < 0.001) and the RI of the TZ was significantly higher (P < 0.001) than in healthy controls and men with CAD. In diabetics and men with PAOD, the mean prostate volume was greater than in healthy controls and men with CAD. The IPSS in patients with vascular damage (diabetes, PAOD) was significantly worse than in the control group.
CONCLUSIONS: The significantly lower CPD and higher RI values of the TZ in patients with vascular disease than in healthy subjects support the hypothesis that an age-related impairment of blood supply to the prostate has a key role in the development of BPH.

Entities:  

Mesh:

Year:  2006        PMID: 16879445     DOI: 10.1111/j.1464-410X.2006.06400.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  23 in total

1.  Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients.

Authors:  Xiaobing Qu; Zhichao Huang; Xianqin Meng; Xiangyu Zhang; Lini Dong; Xiaokun Zhao
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

Review 2.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

3.  Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation.

Authors:  Cahit Sahin; Bilal Eryildirim; A Cihangir Cetinel; Gokhan Faydaci; Fehmi Narter; Cemal Goktas; Kemal Sarica
Journal:  Int Urol Nephrol       Date:  2015-01-15       Impact factor: 2.370

Review 4.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 5.  Cholesterol and benign prostate disease.

Authors:  Michael R Freeman; Keith R Solomon
Journal:  Differentiation       Date:  2011-08-20       Impact factor: 3.880

Review 6.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 7.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

8.  Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.

Authors:  Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

9.  Prostate angiogenesis in development and inflammation.

Authors:  Letitia Wong; Jerry Gipp; Jason Carr; Christopher J Loftus; Molly Benck; Sanghee Lee; Vatsal Mehta; Chad M Vezina; Wade Bushman
Journal:  Prostate       Date:  2013-11-30       Impact factor: 4.104

Review 10.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.